This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meza, J. L. Articles by Meyer, W. H. Search for Related Content PubMed PubMed Citation Articles by Meza, J. L. Articles by Meyer, W. H. Social Bookmarking                            What's this?

Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group

Jane L. Meza, James Anderson, Alberto S. Pappo, William H. Meyer

From the Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK; and the Hospital for Sick Children, Toronto, Ontario, Canada

Address reprint requests to Jane L. Meza, PhD, Department of Preventive and Societal Medicine, 984350 Nebraska Medical Center, Omaha, NE 68198-4350; e-mail: jmeza{at}unmc.edu

PURPOSE: The outcome for localized rhabdomyosarcoma (RMS) or undifferentiated sarcoma (UDS) is affected by age, histology, primary anatomic site, extent of disease, and therapy.

PATIENTS AND METHODS: We evaluated patient and disease characteristics for their ability to predict outcome for patients with nonmetastatic RMS or UDS treated on Intergroup Rhabdomyosarcoma Study (IRS) -III (1984 to 1991) or IRS-IV (1991 to 1997).

RESULTS: The estimated 5-year failure-free survival (FFS) rate was 90% for patients with embryonal RMS (ERMS) stage 1, group I or IIa; stage 2, group I; or group III orbit. The estimated 5-year FFS rate was 87% for patients with ERMS stage 1, group IIb or IIc; stage 1, group III nonorbit; stage 2, group II; and stage 3, group I or II; and 73% for patients with ERMS stage 2 or 3, group III. The estimated 5-year FFS rate was poor for patients with stage 2 or 3, group III ERMS with invasive (T2) tumors who were age younger than 1 year or 10 years or older (56%) and patients with stage 2 or 3, group III extremity primary tumors (43%). Overall, outcomes for patients with alveolar RMS (ARMS) or UDS were worse than for patients with ERMS. However, the 5-year FFS rate was good for patients with ARMS/UDS at favorable sites with group I or II (80%) or group III (76%) disease. The FFS rate was poorer for patients with ARMS/UDS at unfavorable sites with group I or II (66%) or group III (45%) disease. The estimated 5-year FFS rate was 31% for patients with group III ARMS/UDS at unfavorable sites with regional lymph node disease, which is similar to metastatic RMS.

CONCLUSION: Patient and disease characteristics identify distinct subsets with different outcomes, allowing the Soft Tissue Sarcoma Committee of the Children's Oncology Group to refine risk-adapted therapy assignment.

Supported by Grants No. CA-24507 and CA-72989 from the National Cancer Institute.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. A. Rodeberg, J. A. Stoner, A. Hayes-Jordan, S. C. Kao, S. L. Wolden, S. J. Qualman, W. H. Meyer, and D. S. Hawkins Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group J. Clin. Oncol., August 1, 2009; 27(22): 3705 - 3711. [Abstract] [Full Text] [PDF]

				I. Sultan, I. Qaddoumi, S. Yaser, C. Rodriguez-Galindo, and A. Ferrari Comparing Adult and Pediatric Rhabdomyosarcoma in the Surveillance, Epidemiology and End Results Program, 1973 to 2005: An Analysis of 2,600 Patients J. Clin. Oncol., July 10, 2009; 27(20): 3391 - 3397. [Abstract] [Full Text] [PDF]

				T. A. Guise, R. O'Keefe, R. L. Randall, and R. M. Terek Molecular Biology and Therapeutics in Musculoskeletal Oncology J. Bone Joint Surg. Am., March 1, 2009; 91(3): 724 - 732. [Full Text] [PDF]

				F. Diomedi-Camassei, H. P. McDowell, M. A. De Ioris, S. Uccini, P. Altavista, G. Raschella, R. Vitali, O. Mannarino, L. De Sio, D. A. Cozzi, et al. Clinical Significance of CXC Chemokine Receptor-4 and c-Met in Childhood Rhabdomyosarcoma Clin. Cancer Res., July 1, 2008; 14(13): 4119 - 4127. [Abstract] [Full Text] [PDF]